The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to investigate the effect of the GLP-1 analogue Victoza® on psoriasis in a double-blinded, randomized placebo-controlled clinical trial.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Annesofie Faurschou
• Collaborator: University of Copenhagen
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Caucasians above 18 years of age

• Plaque psoriasis

• PASI score >10

• No treatment or stable treatment of psoriasis during at least 3 months before inclusion

• Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2

• Normal blood pressure

• Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (~5 times the plasma half-life)

Exclusion Criteria:

• Psoriasis arthritis

• Fasting plasma glucose > 7.5 mmol/L or HbA1c > 7.5%

• Type 1 diabetes

• Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)

• Heart failure, NYHA class III-IV

• Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >150 µM and/or albuminuria

• Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 x upper normal serum levels)

• Anaemia

• Acute or chronic pancreatitis

• Struma or thyroid cancer

• Pregnancy or breast feeding

• Inability to complete the study